Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 9/20 | 0.40 |
| ▸ | ACHE | P22303 | 9/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4317389 | 1.00 | AURKA (0.47) | AURKAAURKBBCHEACHERAB9A | |
| SCHEMBL4314475 | 0.91 | AURKA (0.47) | AURKAAURKBRAB9ANPC1KDR | |
| SCHEMBL4314491 | 0.91 | AURKA (0.47) | AURKAAURKBRAB9ANPC1KDR | |
| SCHEMBL4327231 | 0.89 | AURKA (0.53) | AURKAAURKBRAB9ANPC1HPGD | |
| SCHEMBL4327238 | 0.89 | AURKA (0.53) | AURKAAURKBRAB9ANPC1HPGD | |
| SCHEMBL4314487 | 0.89 | AURKA (0.48) | AURKAAURKBRAB9ANPC1HPGD | |
| SCHEMBL4314467 | 0.89 | AURKA (0.48) | AURKAAURKBRAB9ANPC1HPGD | |
| SCHEMBL4324776 | 0.85 | AURKA (0.51) | AURKAAURKBKDREGFR | |
| SCHEMBL4324783 | 0.85 | AURKA (0.51) | AURKAAURKBKDREGFR | |
| SCHEMBL4309036 | 0.84 | AURKA (0.51) | AURKAAURKBRAB9ANPC1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1847532-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054508-A1 | IGF-1R INHIBITOR | IGF1R, IGFBP5, IGFBP1 | AURKA 3687/4885AURKB 3438/4885BCHE 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.